Uppsala, Sweden, 2013-08-22 16:48 CEST (GLOBE NEWSWIRE) -- The Oasmia Annual Report for the fiscal year 2012/2013 is now available at the company website www.oasmia.com
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).
Mikael Widell, Vice President Communications, Oasmia Pharmaceutical AB. E-mail: firstname.lastname@example.org Phone: +46 (0) 18 50 54 40. www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia